CC-115
Drug
Celgene Corporation
Total Payments
$982,323
Transactions
31
Doctors
11
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $11,116 | 12 | 11 |
| 2018 | $569,626 | 14 | 11 |
| 2017 | $401,580 | 5 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $982,323 | 31 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-115-CL-PCA-PCCTC-005920 - A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC) | Celgene Corporation | $403,384 | 0 |
| CC-115-CL-PCA-PCCTC-005920 | Celgene Corporation | $336,154 | 0 |
| CC-115-CL-GBM-PI-007141 - INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT) | Celgene Corporation | $125,413 | 0 |
| CC-115-ST-001 - Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered oral | Celgene Corporation | $40,829 | 11 |
| CC-115-ST-001 | Celgene Corporation | $40,344 | 0 |
| CC-115-CL-GBM-PI-007141 | Celgene Corporation | $25,083 | 0 |
| Phase 1a/1b, multicenter, open label, dosefinding study to assess the safety, tolerability, pharmacokinetics & preliminary efficacy of the dual dna-pk & tor kinase inhibitor, cc-115, administered orally to subjects w/ advanced solid tumors & hematologic (CC-115-ST-001) | Celgene Corporation | $11,116 | 11 |
Top Doctors Receiving Payments for CC-115
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $934,693 | 9 |
| , MD | Medical Oncology | San Antonio, TX | $4,330 | 2 |
| , MD | Hematology & Oncology | Tampa, FL | $4,330 | 2 |
| , M.D | Hematology & Oncology | Baltimore, MD | $4,330 | 2 |
| , MD | Internal Medicine | New York, NY | $4,330 | 2 |
| Amit Mahipal | Hematology & Oncology | Rochester, MN | $4,330 | 2 |
| , M.D | Medical Oncology | Houston, TX | $4,330 | 2 |
| , M.D | Neurological Surgery | Detroit, MI | $4,330 | 2 |
| , MD | Internal Medicine | Ann Arbor, MI | $4,330 | 2 |
| , MD | Medical Oncology | Toledo, OH | $4,330 | 2 |
| , MD | Neurology | Los Angeles, CA | $4,330 | 2 |
| , M.D | Medical Oncology | Nashville, TN | $4,330 | 2 |
Ad
Manufacturing Companies
- Celgene Corporation $982,323
Product Information
- Type Drug
- Total Payments $982,323
- Total Doctors 11
- Transactions 31
About CC-115
CC-115 is a drug associated with $982,323 in payments to 11 healthcare providers, recorded across 31 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $11,116 was paid across 12 transactions to 11 doctors.
The most common payment nature for CC-115 is "Unspecified" ($982,323, 100.0% of total).
CC-115 is associated with 7 research studies, including "CC-115-CL-PCA-PCCTC-005920 - A Phase 1b/2 Study of Enzalutamide Plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC)" ($403,384).